L. Seymour - Concepedia

Author

L. Seymour

University of the Witwatersrand

Also Known As

L SEYMOUR, L Seymour, L. Seymour, LK Seymour, Lesley Seymour

Publications

698

Citations

H-Index

Concepts

All Affiliations

University of the Witwatersrand

About

L. Seymour is an author at University of the Witwatersrand specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	274
2	Immunology	5	5	138
3	Health Sciences	3	3	41
4	Cellular Therapies	1	1	10
5	Endocrinology	1	1	22

L. Seymour

Publications

681

Citations

H-Index

Page 1

	Year	Citations
High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. W. R. Bezwoda, L. Seymour, Roger Dansey Journal of Clinical Oncology	1995	407
Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: Correlation with stage and rate of progression Samuel Ariad, L. Seymour, W.R. Bezwoda Breast Cancer Research and Treatment ThrombopoiesisBreast OncologyBlood PlateletPlatelet-derived Growth FactorBreast Cancer Patients	1991	98
Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer L. Seymour, W. R. Bezwoda Breast Cancer Research and Treatment ThrombopoiesisAdvanced Breast CancerBreast OncologyBlood PlateletGrowth Factor	1994	73
P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer L. Seymour, W. R. Bezwoda, Roger Dansey Breast Cancer Research and Treatment Advanced Breast CancerBreast OncologyOncologyHigh Ki67 ExpressionMedicine	1995	24
Estimation of PR and ER by immunocytochemistry in breast cancer. Comparison with radioligand binding methods. L. Seymour, Karin Meyer, J.D. Esser, PubMed Breast OncologyEstrogen ReceptorImmunocytochemical StainingPathologyGynecology	1990	22
Non‐cryopreserved, limited number (1 or 2) peripheral blood progenitor cell (PBPC) collections following GCSF administration provide adequate hematologic support for high dose chemotherapy W. R. Bezwoda, Roger Dansey, L. Seymour, Hematological Oncology Gcsf AdministrationImmunologyBlood CellPathologyMetronomic Chemotherapy	1994	18
First-Line Chemotherapy of Advanced Breast Cancer with Mitoxantrone, Cyclophosphamide and Vincristine W.R. Bezwoda, Roger Dansey, L. Seymour Oncology First-line ChemotherapyAdvanced Breast CancerBreast OncologyMedicineMetronomic Therapy	1989	16
Quantitative analysis of vascular endothelial growth factor expression in chronic lymphocytic leukaemia D Baban, Jaclyn Murray, Helena Earl, International Journal of Oncology ImmunologyPathologyTumor BiologyAngiogenesisOncology	1996	13
Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease L. Seymour, W. R. Bezwoda British Journal of Cancer Single High-dose EtoposidePoor-prognosis HodgkinLymphoid NeoplasiaCell TherapyOncology	1994	10

Page 1